Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

Nature Medicine

Volumn 10, Issue 2, 2004, Pages 148-154

  Tanaka, Motomasa ^a   Machida, Yoko ^a   Niu, Sanyong ^a   Ikeda, Tetsurou ^a   Jana, Nihar R ^a   Doi, Hiroshi ^a   Kurosawa, Masaru ^a   Nekooki, Munenori ^a   Nukina, Nobuyuki ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DISACCHARIDE; POLYGLUTAMINE; TREHALOSE; GLUCOSE; HD PROTEIN, HUMAN; HDH PROTEIN, MOUSE; MYOGLOBIN; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; GENERAL CONDITION IMPROVEMENT; HUNTINGTON CHOREA; IN VITRO STUDY; LIFESPAN; LIVER; MODEL; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INTERACTION; TOXICITY; TRANSGENIC MOUSE; ANIMAL; CELL DEATH; CELL LINE; CYTOLOGY; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ANIMALIA; MUS MUSCULUS;

ANIMALS; BRAIN; CELL DEATH; CELL LINE; DISEASE MODELS, ANIMAL; GLUCOSE; HUMANS; HUNTINGTON DISEASE; LIVER; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MYOGLOBIN; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PEPTIDES; TREHALOSE;

EID: 1642633757     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm985     Document Type: Article

References (39)

1. Zoghbi, H.Y. & Orr, H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247 (2000).
2. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558 (1997).
3. Davies, S.W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (1997).
4. Warrick, J.M. et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93, 939-949 (1998).
5. Lunkes, A. & Mandel, J.L. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet. 7, 1355-1361 (1998).
6. DiFiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
7. Michalik, A. & Van Broeckhoven, C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum. Mol. Genet. 12, R173-R186 (2003).
8. Mccampbell, A. & Fischbeck, K.H. Polyglutamine and CBP: fatal attraction? Nat. Med. 7, 528-530 (2001).
9. Ross, C.A., Poirier, M.A., Wanker, E.E. & Amzel, M. Polyglutamine fibrillogenesis: the pathway unfolds. Proc. Natl. Acad. Sci. USA 100, 1-3 (2003).
10. Bates, G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642-1644 (2003).
11. Ona, V.O. et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267 (1999).
12. Cummings, C.J. et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19, 148-154 (1998).
13. Jana, N.R., Tanaka, M., Wang, G.H. & Nukina, N. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 9, 2009-2018 (2000).
14. Shimohata, T. et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 26, 29-36 (2000).
15. Perez, M.K. et al. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell. Biol. 143, 1457-1470 (1998).
16. Chen, M. et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801 (2000).
17. Ferrante, R.J. et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397 (2000).
18. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 100, 2041-2046 (2003).
19. Sanchez I., Mahlke, C. & Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421, 373-379 (2003).
20. Hughes, R.E. & Olson, J.M. Therapeutic opportunities in polyglutamine disease. Nat. Med. 7, 419-423 (2001).
21. Heiser, V. et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implication for Huntington's disease therapy. Proc. Natl. Acad. Sci. USA 97, 6739-6744 (2000).
22. Heiser, V. et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl. Acad. Sci. USA 99, 16400-16406 (2002).
23. Tanaka, M., Morishima, I., Akagi, T., Hashikawa, T. & Nukina, N. Intra- and intermolecular β-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J. Biol. Chem. 276, 45470-45475 (2001).
24. Tanaka, M. et al. The effects of aggregation-inducing motifs on amyloid formation of model proteins related to neurodegenerative diseases. Biochemistry 41, 10277-10286 (2002).
25. Nagai, Y. et al. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 275, 10437-10442 (2000).
26. Luo, Y. & Baldwin, R.L. Trifluoroethanol stabilizes the pH 4 folding intermediate of sperm whale apomyoglobin. J. Mol. Biol. 279, 49-57 (1998).
27. Wang, G.H. et al. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 10, 2435-2438 (1999).
28. Guo, N., Puhlev, I., Brown, D.R., Mansbridge, J. & Levine, F. Trehalose expression confers desiccation tolerance on human cells. Nat. Biotechnol. 18, 168-171 (2000).
29. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
30. Sathasivam, K. et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. 8, 813-822 (1999).
31. Poirier, M.A. et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277, 41032-41037 (2002).
32. Azzouz, M. et al. Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum. Mol. Genet. 9, 803-811 (2000).
33. Hurlbert, M.S. et al. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48, 649-651 (1999).
34. Farrer, A. Diabetes mellitus in Huntington's disease. Clin. Genet. 27, 62-67 (1985).
35. Singer, M.A. & Lindquist, S. Multiple effects of trehalose on protein folding in vitro and in vivo. Mol. Cell 1, 639-648 (1998).
36. Kazantsev, A. et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 30, 367-376 (2002).
37. Yang, W., Dunlap, J.R. Andrews, R.B. & Wetzel, R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917 (2002).
38. Wellington, C.L. et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 9158-9167 (1998).
39. Kandror, O., DeLeon, A. & Goldberg, A.L. Trehalose synthesis is induced upon exposure of Escherichia coli to cold and is essential for viability at low temperature. Proc. Natl. Acad. Sci. USA 99, 9727-9732 (2002).